| Efficacy and Safety of Middle Meningeal Artery Embolization for Patients with Chron | ıic |
|---|-----|
| Subdural Hematoma: A Systematic Review and Meta-Analysis | |

Kabir N¹, Owais B¹, Trifan G¹, Testai FD¹

hematoma, best medical management

Corresponding author:
Kabir, Nabihah, MD
Department of Neurology and Rehabilitation
University of Illinois College of Medicine at Chicago
Chicago, II, 60612
Email: nabihah@uic.edu

Keywords: chronic subdural hemorrhage, middle meningeal artery embolization, recurrent

¹ Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, Chicago, Il

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

23

24

25

26

Background: Chronic subdural hematoma (CSDH) is characterized by the collection of blood beneath the dura mater. Traditional treatments involve surgical drainage of the hematoma, but recurrence rates can be high. A highly vascularized neo-membrane irrigated by the middle meningeal artery (MMA) may be involved in CSDH re-accumulation. **Objective:** We conducted a systematic review and meta-analysis of studies that compared the efficacy and safety of MMA embolization to conventional treatment alone for CSDH. Material and Methods: A systematic search of PubMed, Embase Ovid, and ClinicalTrials.gov identified observational and randomized clinical studies comparing MMA embolization to conventional treatment for chronic subdural hematoma. The efficacy outcomes were hematoma recurrence and good functional outcome (as defined by a modified Rankin Scale score (mRS) of 0-2). Safety outcomes were the rate of major complication and mortality. Heterogeneity among studies were evaluated using the l² statistic. Analyses were conducted using Cochrane Review Manager software, with risk ratios (RR) and 95% confidence intervals (95% CI) presented for key outcomes. Absolute risk reduction (ARR, 95% CI) 1000 patients were also calculated using GRADEpro software. Results: The analysis included data from 13 studies (4 RCTs and 9 observational studies) with a total number of 2960 patients (35.3% in the MMA group and 64.7% in the conventional treatment group). Compared to conventional treatment, MMA embolization decreased risk of hematoma recurrence by 60% (13 studies, RR=0.40, 95% CI 0.25-0.63; I^2 =50%), for an absolute effect of 119 fewer events/1000 patients (95% CI 70-149), with similar risk of major complications (9 studies, RR=0.82, 95% CI=0.54-1.25) and mortality risk (13 studies, RR=0.90, 22 95% CI=0.54-1.51). In subgroup analyses by study type, pooled results from RCTs showed similar direction effects as those from observational studies for both efficacy and safety outcomes. Conclusion: MMA embolization in CSDH management is a safe and effective approach for CSDH.

<u>Introduction</u>

27

28 29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Chronic subdural hematoma (CSDH) refers to the accumulation of blood, blood-degradation products, of fluid between the dura mater and the arachnoid. CSDH affects preponderantly the elderly and has an estimated incidence of 1.7 to 20.6 per 100,000 persons per year. However, based on the increase in global life expectancy and the trends obtained in observational studies. it is projected that the incidence of this condition will continue to rise². The traditional management of CSDH, which includes surgical drainage, is associated with periprocedural complications and recurrence rates that range from 3% to 30%³. Historically, it was considered that CSDH was the consequence of venous oozing secondary to traumatic injury of the bridging veins. However, cumulative evidence indicates that, although trauma, even if mild, may constitute an initial insult, the pathogenesis of CSDH involves the development of a layer of connective tissue cells that leads to the formation of a new membrane⁴. This membrane is enriched in pro-inflammatory and pro-angiogenic mediators, such as tissue-plasminogen activators, matrix-metalloproteinases, and vascular endothelial growth factor. These mediators contribute to the development of leaky vessels that result in repeated microbleeds and the exudation of fluid. This phenomenon further enhances inflammation and results in a vicious cycle that perpetuates CSDH and contributes to its recurrence. Since the vascular supply to this new membrane derives from the middle meningeal artery (MMA), it has been proposed that the embolization of the MMA may reduce the risk of hematoma growth and recurrence. Since the MMA is a branch of the external carotid artery, it was considered that this procedure would not significantly increase the risk of cerebrovascular complications. Data supporting the benefit and safety of endovascular embolization of the MMA as an adjunct to surgical drainage originates from non-randomized retrospective studies and registries. In a meta-analysis including non-randomized studies, MMA embolization had lower rates of CSDH recurrence and need for surgical rescue with comparable rates of in-hospital

complications⁵. The results of three randomized clinical trials (RCTs) assessing the benefits and risks of MMA embolization as an adjunct therapy for patients with CSDH were recently reported^{6789–11}. Here we present the results of a meta-analysis where we assessed the efficacy and safety of MMA for the treatment of patients with CSDH.

Material and Methods

Our study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines¹². This protocol is registered in PROSPERO, trial number

IDCRD42024515860. Data is available from the corresponding author upon reasonable request.

No informed consent was required from the human subjects given the nature of the analysis.

Eligibility Criteria and Outcomes

This study included randomized controlled clinical trials and observational studies that compared the efficacy and safety of MMA embolization plus standard of care (conservative or surgical treatment) to standard of care alone for patients with CSDH. Studies that only reported outcomes for MMA embolization without separately reporting the outcomes for conventional management only, case reports, and non-peer-reviewed studies were excluded. The primary efficacy outcome was the risk of hematoma recurrence, and the safety outcome was mortality risk. In a secondary analysis, we investigated the risk of good functional outcomes defined as modified Rankin Scale Score (mRS) of 0-2 at follow-up and the frequency of major complications. Supplemental Table 1 depicts the definitions used in each trial. Given the wildly variable definitions for the safety endpoints used in the RCTs (Supplementary Table 2), we only report here the rates of safety points from each RCT, while presenting the pooled results of safety outcomes of the observational studies.

Information Sources and Search Methods

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

We gueried PubMed, Embase Ovid, and ClinicalTrials, gov from inception to February 2024. The search algorithm is shown in **Appendix 1**. The results were screened for inclusion criteria by 2 of the authors (GT and FDT). Disagreements were resolved using the other two authors (NK and BO). Information on trial design, sample size, mean age, sex, laterality of the hematoma (unilateral vs bilateral), etiology, baseline CSDH volume or thickness, and mean follow-up time, along with the safety and efficacy outcomes were collected. **Statistical Analyses and Bias Assessment** Two of the authors (GT and FDT) independently determined the risk of bias in RCTs using the RoB2 (Revised Cochrane Risk of Bias) tool¹³; the risk of bias in nonrandomized studies was assessed using the intervention (ROBINS-I) tool¹⁴. Publication bias was investigated by visual inspection of funnel plots for asymmetry for each reported outcome. Heterogeneity between studies was quantified using l^2 statistic, and as recommended by the American Heart Association¹⁵, using the following cut-offs: 0–40%: might not be important; 30–60%: may represent moderate heterogeneity; 50-90%: may represent substantial heterogeneity; and 75-100%: considerable heterogeneity. To further investigate heterogeneity, subgroup analysis by study design was performed. Analyses were done using Cochrane Review Manager (v 5.4)¹⁶. Descriptive characteristics of the included studies were recorded. Event rates for each efficacy and safety outcome of interest were compared between MMA embolization plus conventional treatment and conventional management alone. Results are presented as risk ratios along with their corresponding 95% confidence intervals (CI), using random-effects Mantel-Haenszel method. The absolute number of events per 1000 patients (absolute risk reduction, 95% CI) was calculated using the GRADEpro software¹⁷.

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Results **Study Selection and Characteristics** The search yielded a total of 3,978 records. Of these, 13 studies with 2,960 patients (35.3% in the MMA group and 64.7% in the conventional treatment group) were included in the final analysis (Figure 1). There were 9 observational studies and 4 RCTs. Three of the RCTs were recently presented at the 2024 International Stroke Conference^{6789–11}. Baseline characteristics of the included studies are presented in **Table 1**. In the MMA group, mean (SD) age was 72.4± 4.6 years, 73.3% were males, and mean SDH thickness was 18± 4.6. Comparatively, in the MMA group mean age was 70.6± 5.4 years, 70% were males, and the mean SDH thickness was 18.5± 4.7 mm. Mean follow-up time between groups was similar among groups (3.2) months). The risk of bias across all studies, and for each included study is shown in Supplementary Figure 1. Visual inspection of the funnel plots revealed symmetry for the main outcomes (Supplementary Figure 2). **Efficacy outcomes** Figure 2 depicts the risk of hematoma recurrence between adjunct MMA embolization and conventional management alone for all studies. There was an absolute effect of 119 fewer events per 1.000 patients (95% CI 70-149) and an overall risk reduction of 60% in favor of adjunct MMA embolization compared with conventional treatment alone (13 studies, RR=0.40, 95% CI 0.25-0.63) with moderate heterogeneity (I²=50%). When analyzing by study design, data from RCTs showed a risk reduction of hematoma recurrence with adjunct MMA embolization of 52% (4 studies, RR=0.48, 95% CI=0.34-0.67), with low heterogeneity ($I^2=15\%$) and an absolute effect of 86 fewer hematoma recurrences per 1.000 participants (95% CI 54-109) (Figure 2). In comparison, observational studies showed a 74% risk reduction for hematoma recurrence in favor of adjunct MMA (RR=0.26, 95% CI= 0.10-0.66) with substantial

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

heterogeneity (I²=64%) and an absolute effect of 167 fewer recurrences per 1,000 participants (95% CI 63-203) (Figure 2). Rates for good functional outcomes were available for 4 studies only (1 RCT and 3 observational studies). Overall risk for good functional outcome was similar between groups (RR=1.02, 95% CI=0.98 -1.06) with no heterogeneity ($I^2=0\%$) (**Figure 2**). Safety outcomes Figure 3 depicts the risk of major complications and mortality rates. Overall, the pooled risk of major complications for all observational studies was 29% lower in the MMA group compared with conventional treatment alone (9 studies, RR=0.82, 95% CI 0.54-1.25) with no heterogeneity (I²=0%). The safety endpoint rates reported in each RCT varied between 5% to 16% for the MMA group, compared to 4% to 22% in the conventional treatment group. Mortality rates were similar as well for both groups (13 studies, RR=0.90, 95% CI=0.54 -1.51) with no heterogeneity (l²=0%). When analyzed by study design, mortality rates were comparable for RCTs (RR=0.82. 95% CI 0.28-2.34; I²=45%) and observational studies (RR=0.87, 95% CI=0.42-1.81, I²=0%) (Figure 3). **Discussion** The results of our meta-analysis show that MMA embolization added to conventional treatment is superior to conventional treatment alone for the treatment of CSDH. Previous meta-analyses that included data from retrospective cohorts have shown that MMA embolization is associated with lower rates of hematoma recurrence and fewer complications¹⁵. However, the lack of data from RCTs confounded the interpretation of these results. Limitations like retrospective data and lack of separate reporting for conventional treatment hampered their generalizability⁵. This updated meta-analysis addresses these issues by including recent RCTs and observational studies with direct comparisons between MMA embolization with adjunct standard care and standard care alone. In our study, which included the results from three new RCTs⁶⁷⁸, we

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

observed a 60% reduction in overall hematoma recurrence risk in favor of MMA embolization plus conventional treatment compared to conventional treatment alone, for an absolute risk reduction of 86 fewer hematoma recurrences per 1000 participants. In the subgroup analysis by study design, the rate of hematoma recurrence reduction in favor of MMA was higher in observational studies than in RCTs (74% vs. 52%). These differences could be explained, at least in part, by methodologic factors, including patient selection, publication bias, and study design. Also, several studies reported outcomes obtained in small cohorts which can increase the type II error. Furthermore, the wide confidence intervals and moderate heterogeneity observed in observational studies suggest elevated variability in the reported outcomes and raise concerns about the precision of the calculated point estimates. In comparison, the analysis using data from RCTs produced estimates with narrower confidence intervals and low heterogeneity. Thus, the inclusion of adequately powered RCTs allows for a more accurate estimation of the effect of MMA embolization on CSDH outcomes. This finding strengthens the evidence for the efficacy of MMA embolization in chronic subdural hematoma. The surgical interventions used for the treatment of CSDH, like burr-hole evacuation, are considered safe. However, the rate of perioperative complications and mortality observed in CSDH cohorts varies from 0% to 32%. These complications are not always caused by the surgical procedure itself but are secondary to other factors such as preexisting active medical conditions and frailty^{18,19}. MMA embolization, which is typically done endovascularly, is well tolerated and is also considered safe. The MMA contributes minimally to cerebral blood flow. and collateral circulation can effectively compensate for the blocked MMA, minimizing the risk of cerebrovascular complications. Additionally, embolization is performed via the external carotid artery, further reducing the risk of ischemic stroke²⁰. The overall incidence of complications in cohorts treated with MMA embolization is less than 4%²¹. The safety of MMA embolization is also supported by the results of previous meta-analyses which reported similar complication

rates for adjunct MMA embolization and conventional treatment groups. ⁵ ²² In our study, there were no significant differences in the safety endpoint or mortality for the pooled results, indicating that MMA embolization plus conventional treatment provides a safe alternative to conventional management alone for CSDH. Future studies should assess the long-term durability of the MMA effect and whether this approach allows the use of anticoagulation in patients who require such treatment. Similar to previous studies, we observed that MMA embolization as an adjunct treatment does not improve functional outcomes compared to conventional management alone²². However, it should be noted that most of the studies included in this analysis ascertained functional outcomes using the mRS. This scale is widely used in stroke research. However, the sensitivity of this tool to detect differences in disability in the particular case of SDH, where the neurologic deficits may be subtle, has not been well described.

Limitations

Our meta-analysis has several limitations. First, the conventional treatment was not standardized among studies; thus, there are intrinsic variations among the studies that we are not able to account for. Second, there is variability in the definitions of efficacy and safety outcomes among studies. Third, the majority of the studies included in our analysis had an observational retrospective design with the consequent risk of selection bias²³. In addition, many of them were performed in small cohorts and did not include power calculations. However, in subgroup analysis, we observed that the results reported in observational studies are comparable to those obtained in adequately powered RCTs. Fourth, we reported our results as RRs and absolute effects. Because the absolute risk for control varies between trials, these estimates should be interpreted with caution. However, our meta-analysis is the largest study comparing the efficacy and safety of MMA as adjunct therapy to standard treatment alone for patients with CSDH. In addition, we included the results of three large RCTs which, combined,

accounted for almost 75% of the final sample size and allowed us to calculate point estimates with low heterogeneity.

Conclusion

MMA embolization as an adjunct treatment significantly decreases the recurrence of CSDH without increasing the risk of morbidity or mortality when compared to conventional treatment alone. Several studies are currently underway to compare the efficacy and safety of MMA embolization as a standalone treatment for CSDH.

Table 1. Baseline Characteristics ⁵

| Study, year | Design | Sample size | | Lost to follow up/Exited, n(%) | | Mean mm ±SD or median (IQR) age | | Male, N(%) | | Traumatic SDH, n(%) | | Bilateral SDH, n(%) | | | | Mean follow-up time (months) | |
|--------------------------|--------|----------------------|------------------|-----------------------------------|------------------|------------------------------------|-------------------------------|----------------------|------------------|---------------------|------------------|---------------------|------------------|-------------------------|-------------------------|------------------------------|------------------|
| | | MMA Treatme nt | Conve ntional | MMA treatment | Conven tional | MMA Treatme nt | Conve ntional | MMA Treatmen t | Conve ntional | MMA Treatment | Conve ntional | MMA Treatment | Conve ntional | MMA Treatme nt | Conve ntional | MMA Treatme nt | Conve ntional |
| EMBOLISE, 2024 | RCT | 197 | 203 | 30 (15) | 23 (11) | 72.98±11. 01 or [74.7] | 70.99±1 1.28 or [72.5] | 72.60% | 73.40 % | NR | NR | 21.30% | 18.20 % | 21.6±6.3 | 21.4±6. | 3 | 3 |
| MAGIC-MT, 2024 | RCT | 360 | 362 | NR | NR | 68.5 (60- 74) | 70 (61- 75) | 81.10% | 84% | 178 (49.4) | 201 (55.5) | NR | NR | 22.8 (18.6- 27.1) | 22.4(1 8.5- 26.8) | 3 | 3 |
| STEM, 2024 | RCT | 149 | 161 | NR | NR | 74.2 ± 9.8 | 74.2±10 .3 | 67.2 | 74.5 | NR | NR | NR | NR | NR | NR | 3 | 3 |
| Onyinzo et al, 2021 | OR | 50 | 82 | 28 (56%) | 31 (37%) | 79.2 | 77.4±10 .3 | 42 (84%) | 53 (65%) | NR | NR | NR | NR | 21 | 23.5±4. 7 | 3 | 3 |
| Marulanda et al, 2021 | OR | 25 | 25 | 0 | 0 | 75 (70- 87) | 82(67- 88) | 14 (56) | 16 (64) | 10 (40) | 7 (28) | 0 (0) | 0(0) | 19(14- 23.4) | 18.1 (10.9- 26.1) | 2 | 3 |
| Catapano et al, 2021 | OR | 35 | 196 | NR | NR | 68±12 | 71±13 | 25 (71%) | 139 (71%) | 23 (66%) | 144 (73%) | 6 (17%) | 86 (43%) | 15±3.9 | 15.3 | 3-4 | 3-4 |
| Carpenter et al, 2021 | OR | 23 | 185 | 1 (4%) | 5 (2%) | 61±6.2 | 70.2±12 .6 | 18 (82%) | 123 (67%) | NR | NR | 4 (17%) | 46 (25%) | 18±6 | 18±5 | 3-4 | 3-4 |
| Shotar et al, 2020 | OR | 89 | 174 | 6 (6%) | 12 (6%) | 74±13 | 77±12 | 68 (76%) | 123 (71%) | NR | NR | 15 (17%) | 36 (21%) | NR | NR | 3 | 3 |
| Ng et al, 2019 | RCT | 21 | 25 | 1 (5) | 2 (8) | 77.4±10.9 | 74.7±13 .9 | 10 (53) | 13 (59) | 12 (63) | 15 (68) | 3 (16) | 3 (14) | 6.4±5.7 | 6.8±5.3 | 3 | 3 |
| Ban et al, 2018 | OP | 72 | 469 | 0 | 0 | 69.3±10.4 7 | 67.4±13 .16 | 48 (67%) | 347 (74%) | 45 (62%) | 272 (58%) | 19 (26%) | 107 (23%) | 19.6±5.00 | 20.3±6. 47 | 3-6 | 3-6 |
| Matsumoto et al, 2018 | OR | 4 | 10 | 0 | 0 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 3 | 3 |
| Kim et al, 2017 | OR | 20 | 23 | 0 | 0 | 73.65±7.1 4 | 65.65±6 .91 | 14 (70.0) | 16(69. 6) | 8 | 17 | 6 | 1 | 18.9±7.58 | 21.01± 6.21 | 3 | 3 |
| Lam et al, 2023 | RCT | 16 | | 0 | 3 | _ | | 12 | 11 | 13 | 16 | 9 | 4 | 21.1 | 20.9 | 3 | 3 |

RCT-randomized control trial; OR-observational retrospective study; OP-observational prospective trial; NR=not reported

Figure 1. PRISMA Flow Diagram







Figure 2. Efficacy outcome with and without MMA embolization.






Risk ratio for hematoma recurrence (A), and good functional outcome (mRS ≤2) (B) for patients receiving adjunct MMA embolization to conventional management vs conventional management only. M-H indicates the Mantel-Haenszel method; RCT: Randomized control trial.

Figure 3. Safety Outcomes with and without MMA embolization





Risk ratio for safety endpoints (C), as reported in each trial, and mortality (D) for patients receiving adjunct MMA embolization to conventional management vs conventional management only. M-H indicates Mantel-Haenszel method.

References


- 1. Feghali J, Yang W, Huang J. Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome. *World Neurosurgery*. 2020;141:339-345. doi:10.1016/j.wneu.2020.06.140
- 2. Rauhala M, Helén P, Huhtala H, et al. Chronic subdural hematoma—incidence, complications, and financial impact. *Acta Neurochir*. 2020;162(9):2033-2043. doi:10.1007/s00701-020-04398-3
- 3. Balser D, Farooq S, Mehmood T, Reyes M, Samadani U. Actual and projected incidence rates for chronic subdural hematomas in United States Veterans Administration and civilian populations. *JNS*. 2015;123(5):1209-1215. doi:10.3171/2014.9.JNS141550
- 4. Ducruet AF, Grobelny BT, Zacharia BE, et al. The surgical management of chronic subdural hematoma. *Neurosurg Rev.* 2012;35(2):155-169. doi:10.1007/s10143-011-0349-y
- 5. Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. *J NeuroIntervent Surg.* 2021;13(10):951-957. doi:10.1136/neurintsurg-2021-017352
- 6. Davies J, Knopman J. Embolization of the Middle Meningeal Artery With ONYX[™] Liquid Embolic System for Subacute and Chronic Subdural Hematoma (EMBOLISE). ClinicalTrials.gov. Published June 24, 2024. https://clinicaltrials.gov/study/NCT04402632?tab=history&a=9#study-details-card
- 7. Mao Y. Managing Non-acute Subdural Hematoma Using Liquid Materials: a Chinese Randomized Trial of MMA Treatment (MAGIC-MT). ClinicalTrials.gov. Published April 30, 2024. https://clinicaltrials.gov/study/NCT04700345
- 8. Fiorella D, Arthur A. The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) (STEM). ClinicalTrials.gov. Published August 16, 2023. https://clinicaltrials.gov/study/NCT04410146
- 9. Davies J, Knopman J. Embolise Study Interim Results from the Surgery Cohort. In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3767
- Mao Y. Managing non-Acute SDH using liquid materials: a chinese randomized trial of MMA Treatment (MAGIC-MT). In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3768
- Fiorella D, Arthur A. Squid Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma - Stem Trial. In: ; 2024. https://www.abstractsonline.com/pp8/#!/10942/presentation/3770
- 12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Journal of Clinical Epidemiology*. 2009;62(10):e1-e34. doi:10.1016/j.jclinepi.2009.06.006

- 13. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. Published online August 28, 2019:l4898. doi:10.1136/bmj.l4898
- 14. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. Published online October 12, 2016:i4919. doi:10.1136/bmj.i4919
- Rao G, Lopez-Jimenez F, Boyd J, et al. Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association. *Circulation*. 2017;136(10). doi:10.1161/CIR.0000000000000523
- 16. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020. [n.d].
- 17. GRADEpro software. Accessed February 28, 2024. https://gdt.gradepro.org/app/#projects/p_6a2cde5c-d39f-5fc9-8c87-1b9daae8942b_5d34fc4a-0465-46ba-a73b-820cdd349f02/evidence-syntheses/9dea65cc-bd3e-493d-9136-0057bbe093e1/quality-of-evidence
- 18. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. *Nat Rev Neurol*. 2014;10(10):570-578. doi:10.1038/nrneurol.2014.163
- Atefi N, Alcock S, Silvaggio JA, Shankar J. Clinical Outcome and Recurrence Risk of Chronic Subdural Hematoma After Surgical Drainage. *Cureus*. 2023;15(2):e35525. doi:10.7759/cureus.35525
- 20. Désir LL, D'Amico R, Link T, et al. Middle Meningeal Artery Embolization and the Treatment of a Chronic Subdural Hematoma. *Cureus*. Published online October 18, 2021. doi:10.7759/cureus.18868
- Gerstl J, Shafi M, Badikol S, et al. E-049 Complications of middle meningeal artery embolization – a systematic review. In: SNIS 20th Annual Meeting Electronic Poster Abstracts. BMJ Publishing Group Ltd.; 2023:A105.1-A105. doi:10.1136/jnis-2023-SNIS.149
- 22. Sattari SA, Yang W, Shahbandi A, et al. Middle Meningeal Artery Embolization Versus Conventional Management for Patients With Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis. *Neurosurgery*. 2023;92(6):1142-1154. doi:10.1227/neu.000000000000365
- 23. Lu H, Cole SR, Howe CJ, Westreich D. Toward a Clearer Definition of Selection Bias When Estimating Causal Effects. *Epidemiology*. 2022;33(5):699-706. doi:10.1097/EDE.00000000001516

Supplemental Data:


Supplementary Figure 1: Risk of bias across and between studies.

Risk of bias summary for each individual study. Authors' judgments about each risk of bias item for each included study.




Key: ●: Low risk; ?: Unclear Risk; ●: High Risk

Aggregated risk of bias presented as percentages across all included studies.



Supplementary Figure 2: Risk of bias plots




Funnel plots for risk of bias by study type. Funnel plots obtained for all the studies included in the meta-analysis for hematoma recurrence (panel A), rates of reported good functional outcome (mRS <2) (panel B), risk of safety endpoints (panel C) and mortality risk (panel D).

Supplemental Table 1. Hematoma Recurrence as defined in each study

| Study | Hematoma Recurrence |
|-----------------------|--|
| EMBOLISE, 2024 | hematoma recurrence/progression requiring surgical drainage |
| MAGIC-MT, 2024 | hematoma maximum thickness exceeding 10 mm at 90 days or the patient receiving re-operation within 90 days in patients who underwent burr-hole drainage |
| STEM, 2024 | Residual or re-accumulation of the SDH (≥10 mm) on 180-day scan from intervention |
| Onyinzo et al, 2021 | CT findings in the follow-up period residual CSDH > 10mm |
| Marulanda et al, 2021 | Recurrence was defined as reaccumulating hematoma or continuous growth discovered on follow-up imaging with or without a new acute/subacute component |
| Catapano et al, 2021 | residual cSDH or reaccumulation > 10 mm |
| Carpenter et al, 2021 | re-accumulation of hematoma with symptoms requiring reoperation |
| Shotar et al, 2020 | reoperation to treat a recurrent CSDH previously treated by burr-hole craniostomy |
| Ng et al, 2019 | any radiologically persistent subdural collection with persistent or new symptoms attributable to CSDH |
| Ban et al, 2018 | incomplete hematoma resolution (remaining or reaccumulated hematoma with thickness > 10 mm |
| Matsumoto et al, 2018 | residual hematoma thickness of more than 50% or the absence of size reduction |
| Kim et al, 2017 | increase in the hematoma density and width |
| Salih et al, 2023 | SDH expansion after intervention or appearance of new acute components that warranted intervention or continuous close clinical and radiographic follow-up |
| Lam et al, 2023 | radiologically persistent or new cSDH with persistent or new symptoms secondary to the mass effect of the cSDH |

Supplemental Table 2 . Safety End Points as defined in each study

| Study | Safety End Points |
|-----------------------|--|
| EMBOLISE, 2024 | Neurologic*, Brain abscessCerebellar/cerebral hemorrhage Cerebral infarctionDementiaEncephalopathyExtradural hematoma Gait disturbance Headache Neurological decompensation Neurological symptom Pneumocephalus Procedural complication Seizure/status epilepticusSOHSubduralWound infection Non-Neurologic*AnemiaAstheniaAtrial fibrillationCardiac arrestDysphagia Hepatic encephalopathyHypotensionMalnutritionNeuropathy (peripheral) PneumoniaRespiratory failure |
| MAGIC-MT, 2024 | Symptomatic intracranial hemorrhage Surgery-related intracranial hemorrhage Surgery-related neurological deficits Surgery-related central nervous system infection Surgery-related arterial dissection, vascular wall injury and vascular reperforation Surgery-related ischemia Retroperitoneal/wrist hematoma Neuropathy at the puncture site Contrast allergy or contrast encephalopathy |
| STEM, 2024 | Major disabling stroke, an increase in the NIHSS of 4 points or more from baseline that persists for 24 or more hours from the time of the event (major stroke), and results in a mRS of 3 or greater at 90 days from the event (disabling stroke) |
| Onyinzo et al, 2021 | hematoma re-accumulation, acute re-bleeding, CSF fistula |
| Marulanda et al, 2021 | Complications not defined/described after matching |
| Catapano et al, 2021 | Overall Complications not defined |
| Carpenter et al, 2021 | Seizure, pneumonia, urinary tract infections, acute kidney injury, stroke, DVT/PE, sepsis |
| Shotar et al, 2020 | Epilepsy, empyema |
| Ng et al, 2019 | surgical reoperation |
| Ban et al, 2018 | Treatment related complication, Cerebral infarction |
| | Treatment related complication, acute epidural or subdural hematoma |
| | Treatment related complication, Surgical infection |
| | Treatment related complication, intracerebral hemorrhage |
| Matsumoto et al, 2018 | surgical complications |
| Kim et al, 2017 | surgical complications: intracranial bleeding, wound hematomas, post operative hemorrhage |
| | medical complications: seizure, angina pectoris, urinary tract infection, pneumonia and delirium |
| Salih et al, 2023 | NR |
| Lam et al, 2023 | Infection, new neurological deficits, seizures, pseudoaneurysms, retroperitoneal hemorrhage, allergic reactions to contrast or medications, stroke, intracerebral, hemorrhage, carotid dissection, deep vein thrombosis, pulmonary embolism, myocardial infarction |



Pubmed search algorithm

Search number Query Sort By Filters Search Details Results

4 ((((Middle Meningeal Artery Embolization) AND (chronic subdural hematoma)) AND (outcomes)) AND (surgery)) OR (burr hole)) AND (recurrence) ((("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]) AND ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations" [All Fields] OR "embolise" [All Fields] OR "embolised" [All Fields] OR "embolising" [All Fields] OR "embolism" [MeSH Terms] OR "embolism" [All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields]) AND ("chronic subdural haematoma" [All Fields] OR "hematoma, subdural, chronic" [MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR ("chronic"[All Fields] AND "subdural"[All Fields] AND "hematoma"[All Fields])) AND ("outcome"[All Fields] OR "outcomes"[All Fields]) AND ("surgery" [MeSH Subheading] OR "surgery" [All Fields] OR "surgical procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND "operative"[All Fields]) OR "operative surgical procedures"[All Fields] OR "general surgery" [MeSH Terms] OR ("general" [All Fields] AND "surgery" [All Fields]) OR "general surgery" [All Fields] OR "surgery s" [All Fields] OR "surgerys"[All Fields] OR "surgeries"[All Fields])) OR ("trephining"[MeSH Terms] OR "trephining"[All Fields] OR ("burr"[All Fields] AND "hole"[All Fields]) OR "burr hole"[All Fields])) AND ("recurrance" [All Fields] OR "recurrence" [MeSH Terms] OR "recurrence" [All Fields] OR

"recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields]) 710 3 ((((Middle Meningeal Artery Embolization) AND (chronic subdural hematoma)) AND (outcomes)) AND (surgery)) OR (burr hole) (("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]) AND ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised"[All Fields] OR "embolising"[All Fields] OR "embolism"[MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolisations"[All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes" [All Fields] OR "embolizing"[All Fields]) AND ("chronic subdural haematoma"[All Fields] OR "hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR ("chronic"[All Fields] AND "subdural"[All Fields] AND "hematoma"[All Fields])) AND ("outcome"[All Fields] OR "outcomes"[All Fields]) AND ("surgery"[MeSH Subheading] OR "surgery"[All Fields] OR "surgical procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND "operative"[All Fields]) OR "operative surgical procedures"[All Fields] OR "general surgery"[MeSH Terms] OR ("general"[All Fields] AND "surgery"[All Fields]) OR "general" surgery"[All Fields] OR "surgery s"[All Fields] OR "surgerys"[All Fields] OR "surgeries"[All Fields])) OR ("trephining"[MeSH Terms] OR "trephining"[All Fields] OR ("burr"[All Fields] AND "hole"[All Fields]) OR "burr hole"[All Fields]) 3,978 2 (hematoma, subdural, chronic (MeSH)' OR 'chronic" OR 'subdural hematoma' AND 'meningeal arteries (MeSH)' OR 'middle meningeal artery' AND 'embolization, therapeutic'

(MeSH) OR 'embolization' AND 'recurrence') OR (embolization and recurrence) ((((((("hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR "hematoma subdural chronic"[All Fields]) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("chronic"[All Fields] OR "chronical"[All Fields] OR "chronically" [All Fields] OR "chronicities" [All Fields] OR "chronicity" [All Fields] OR "chronicization"[All Fields] OR "chronics"[All Fields]) OR ("subdural haematoma"[All Fields] OR "hematoma, subdural"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields]) OR "subdural hematoma"[All Fields] OR ("subdural"[All Fields] AND "hematoma"[All Fields]))) AND ("meningeal arteries" [MeSH Terms] OR ("meningeal" [All Fields] AND "arteries" [All Fields]) OR "meningeal arteries" [All Fields])) AND ("medical subject headings" [MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR (("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries" [All Fields]) OR "meningeal arteries" [All Fields] OR ("meningeal" [All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]))) AND ("embolization, therapeutic" [MeSH Terms] OR ("embolization" [All Fields] AND "therapeutic" [All Fields]) OR "therapeutic embolization"[All Fields] OR "embolization therapeutic"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised" [All Fields] OR "embolising" [All Fields] OR "embolism" [MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic" [MeSH Terms] OR ("embolization" [All Fields] AND "therapeutic" [All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields]

OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields])) AND ("recurrance"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields])) OR (("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations" [All Fields] OR "embolise" [All Fields] OR "embolised" [All Fields] OR "embolising"[All Fields] OR "embolism"[MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic"[MeSH Terms] OR ("embolization"[All Fields] AND "therapeutic"[All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolisations"[All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes" [All Fields] OR "embolizing"[All Fields]) AND ("recurrance"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields])) 19,903 1 (hematoma, subdural, chronic (MeSH)' OR 'chronic' OR 'subdural hematoma' AND 'meningeal arteries (MeSH)' OR 'middle meningeal artery' AND 'embolization, therapeutic' (MeSH) OR 'embolization' AND 'recurrence') OR (conventional management) (((((((("hematoma, subdural, chronic"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields] AND "chronic"[All Fields]) OR "chronic subdural hematoma"[All Fields] OR "hematoma subdural chronic"[All Fields]) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("chronic"[All Fields] OR "chronical"[All Fields] OR "chronically"[All Fields] OR "chronicities" [All Fields] OR "chronicity" [All Fields] OR "chronicization" [All Fields] OR "chronics"[All Fields]) OR ("subdural haematoma"[All Fields] OR "hematoma, subdural"[MeSH Terms] OR ("hematoma"[All Fields] AND "subdural"[All Fields]) OR "subdural hematoma"[All

Fields] OR ("subdural"[All Fields] AND "hematoma"[All Fields]))) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR (("middle"[All Fields] OR "middles"[All Fields]) AND ("meningeal arteries"[MeSH Terms] OR ("meningeal"[All Fields] AND "arteries"[All Fields]) OR "meningeal arteries"[All Fields] OR ("meningeal"[All Fields] AND "artery"[All Fields]) OR "meningeal artery"[All Fields]))) AND ("embolization, therapeutic" [MeSH Terms] OR ("embolization" [All Fields] AND "therapeutic" [All Fields]) OR "therapeutic embolization"[All Fields] OR "embolization therapeutic"[All Fields])) AND ("medical subject headings"[MeSH Terms] OR ("medical"[All Fields] AND "subject"[All Fields] AND "headings"[All Fields]) OR "medical subject headings"[All Fields] OR "mesh"[All Fields])) OR ("embol"[All Fields] OR "embolics"[All Fields] OR "embolisations"[All Fields] OR "embolise"[All Fields] OR "embolised" [All Fields] OR "embolising" [All Fields] OR "embolism" [MeSH Terms] OR "embolism"[All Fields] OR "embolic"[All Fields] OR "embolisms"[All Fields] OR "embolization, therapeutic" [MeSH Terms] OR ("embolization" [All Fields] AND "therapeutic" [All Fields]) OR "therapeutic embolization"[All Fields] OR "embolisation"[All Fields] OR "embolization"[All Fields] OR "embolizations" [All Fields] OR "embolize" [All Fields] OR "embolized" [All Fields] OR "embolizes"[All Fields] OR "embolizing"[All Fields])) AND ("recurrance"[All Fields] OR "recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "recurrences"[All Fields] OR "recurrencies"[All Fields] OR "recurrency"[All Fields] OR "recurrent"[All Fields] OR "recurrently"[All Fields] OR "recurrents"[All Fields])) OR (("conventional"[All Fields] OR "conventionals"[All Fields]) AND ("manage"[All Fields] OR "managed"[All Fields] OR "management s"[All Fields] OR "managements"[All Fields] OR "manager"[All Fields] OR "manager s"[All Fields] OR "managers"[All Fields] OR "manages"[All Fields] OR "managing"[All Fields] OR "managment"[All Fields] OR "organization and administration"[MeSH Terms] OR

("organization"[All Fields] AND "administration"[All Fields]) OR "organization and administration"[All Fields] OR "management"[All Fields] OR "disease management"[MeSH Terms] OR ("disease"[All Fields] AND "management"[All Fields]) OR "disease management"[All Fields])) 91,460

ClinicalTrials.gov

NCT Number

Interventions

NCT04410146

for Treatment of Chronic Subdural Hematoma (STEM)

https://clinicaltrials.gov/study/NCT04410146 ACTIVE NOT RECRUITING Subdural Hematoma,

Chronic DEVICE: SQUID Embolization DEVICE: SQUID Embolization and Surgical

Evacuation|PROCEDURE: Surgical Evacuation|OTHER: Other: Medical Management Balt USA

INTERVENTIONAL

Study Title Study URL Study Status Conditions

Sponsor Collaborators Study Type

The SQUID Trial for the Embolization of the Middle Meningeal Artery

NCT03307395 Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT03307395 COMPLETED Chronic Subdural Hematoma PROCEDURE: Middel Meningeal Artery Embolization Weill Medical College of Cornell University INTERVENTIONAL

NCT04500795 Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma https://clinicaltrials.gov/study/NCT04500795 WITHDRAWN Chronic Subdural Hematoma|Subdural Hematoma PROCEDURE: Middle meningeal artery embolization Chinese University of Hong Kong

INTERVENTIONAL

NCT04270955 Dartmouth Middle Meningeal Embolization Trial (DaMMET)

https://clinicaltrials.gov/study/NCT04270955 COMPLETED Chronic Subdural

Hematoma|Subdural Hematoma PROCEDURE: Embolization of the Middle Meningeal

Artery|PROCEDURE: Standard of care including possible surgical evacuation of subdural

hematoma Dartmouth-Hitchcock Medical Center

INTERVENTIONAL

NCT04511572 Embolization of Middle Meningeal Artery in Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04511572 RECRUITING Chronic Subdural Hematomas PROCEDURE: embolization of the middle meningeal artery Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) INTERVENTIONAL NCT04574843 Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04574843 RECRUITING Chronic Subdural Hematoma PROCEDURE: Embolization of MMA Mashhad University of Medical Sciences

NCT05374681 Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization https://clinicaltrials.gov/study/NCT05374681 RECRUITING Chronic Subdural Hematoma OTHER: Medical treatment|OTHER: Surgical treatment|OTHER: embolization of the MMA University Hospital, Brest

INTERVENTIONAL

INTERVENTIONAL

NCT04742920 The Onyxâ,¢ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS) https://clinicaltrials.gov/study/NCT04742920 RECRUITING Hematoma, Subdural, Chronic|Brain Diseases|Central Nervous System Diseases|Wounds and Injuries

DEVICE: Middle Meningeal Artery Embolization|PROCEDURE: Standard Management University Hospital, Montpellier INTERVENTIONAL

NCT04095819 Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)

https://clinicaltrials.gov/study/NCT04095819 UNKNOWN Chronic Subdural Hematoma PROCEDURE: Middle Meningeal Artery procedure|PROCEDURE: Traditional Surgery Atlantic Health System INTERVENTIONAL

NCT06274580 Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms https://clinicaltrials.gov/study/NCT06274580

NOT_YET_RECRUITING Subdural Hematoma, Chronic DEVICE: embolization of the middle meningeal artery Ospedale Policlinico San Martino

INTERVENTIONAL

NCT04816591 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA https://clinicaltrials.gov/study/NCT04816591

RECRUITING Chronic Subdural Hematoma DEVICE: Experimental: Interventional Cohort: Treatment Arm|OTHER: Active Comparator: Interventional Cohort: Control Arm|DEVICE: Experimental: Observational Cohort: Treatment Arm|OTHER: Active Comparator: Observational Cohort: Control Arm Cerenovus, Part of DePuy Synthes Products, Inc. INTERVENTIONAL NCT04065113 Middle Meningeal Artery Embolization for Chronic Subdural Hematoma https://clinicaltrials.gov/study/NCT04065113 RECRUITING Chronic Subdural Hematoma PROCEDURE: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|PROCEDURE: Drainage of Subdural Hematoma Washington University School of Medicine INTERVENTIONAL

NCT05327933 Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by
Middle Meningeal Artery Embolization https://clinicaltrials.gov/study/NCT05327933
RECRUITING Hematoma, Subdural, Chronic PROCEDURE: Surgery plus endovascular MMA
embolization|PROCEDURE: Surgery

alone Unfallkrankenhaus Berlin INTERVENTIONAL

NCT06163547 Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM) https://clinicaltrials.gov/study/NCT06163547 NOT YET RECRUITING

Chronic Subdural Hematomas|Cerebral Compression Due to Injury RADIATION: MMA
embolization University Hospital, Geneva INTERVENTIONAL

NCT04372147 Embolization of the Middle Meningeal Artery for the Prevention of
Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

https://clinicaltrials.gov/study/NCT04372147 UNKNOWN Chronic Subdural Hematoma|at
Risk of Post-operative Recurrence|Burr-hole Surgery PROCEDURE: MMA embolization

Assistance Publique - HÃ pitaux de Paris INTERVENTIONAL